My stomach is eating itself, and medicine has given up.
Bryan Johnson, the tech entrepreneur who has made reversing human aging his public mission, has been diagnosed with autoimmune gastritis — a rare, incurable condition in which the body quietly destroys its own stomach lining. The disease had been silently advancing for eleven years, even as Johnson monitored hundreds of biomarkers in pursuit of what he calls conquering death. His diagnosis is a quiet reckoning with the limits of self-optimization, and a reminder that the body's inner rebellions do not always announce themselves to even the most vigilant observer. Rather than accept medicine's concession of defeat, Johnson is now turning his data-driven philosophy toward the disease itself.
- A man who has spent millions engineering his own immortality has discovered an incurable disease had been living inside him, undetected, for over a decade.
- Autoimmune gastritis causes irreversible stomach damage, nutritional deficiency, anemia, and a rising risk of gastric cancer — and conventional medicine offers no cure, only management.
- The diagnosis exposes a troubling gap: even obsessive biomarker tracking failed to catch an autoimmune condition that routine screening almost never tests for.
- Johnson is refusing the standard prognosis, assembling a team to pursue experimental interventions — biopsies, cytokine profiling, T-cell analysis — treating his own immune system as a problem to be reverse-engineered.
- The race is against irreversible damage already in progress, with gastrin levels serving as the critical warning signal for advancing disease and escalating cancer risk.
Bryan Johnson, the 48-year-old entrepreneur behind Project Blueprint — his multimillion-dollar effort to reverse aging through rigorous self-experimentation — announced in May that he has autoimmune gastritis, a rare disorder in which the immune system turns against the stomach's own lining. For someone whose public identity is built around defeating death, the diagnosis arrived as a particular kind of jolt.
The disease had been advancing in silence for eleven years. During that time, Johnson's blood work consistently showed low ferritin levels that diet and supplements could never correct — a pattern his team noticed but could not explain. Only when he pursued more advanced testing did the picture finally come together. Between two and five percent of the population carries this diagnosis, he noted, though many cases go undetected because early-stage autoimmune gastritis often produces no symptoms at all.
The condition's origins stretch back further still. Johnson traced a thread from a childhood of sugary cereals and fast food, through the stress of early fatherhood and entrepreneurship, to a period of weight gain and depression during which his body first began attacking itself — first his thyroid at twenty-one, then his stomach lining, quietly, for years afterward.
The stakes are concrete: autoimmune gastritis causes irreversible damage, depletes essential nutrients, can trigger anemia, and over time elevates the risk of gastric neuroendocrine tumors. Standard medicine, Johnson noted with evident frustration, offers no cure — only symptom management. His response has been characteristically defiant. He has assembled a team to pursue experimental interventions, tracking a detailed panel of markers including gastrin — the critical signal for disease progression — while conducting repeat biopsies, cytokine profiling, and T-cell analysis to map exactly which immune mechanisms have gone wrong.
The diagnosis raises an uncomfortable question at the heart of the biohacking project: Johnson had access to resources, data, and medical expertise that most people will never possess, and still the disease took root and flourished undetected. He now faces the task of managing an incurable condition while simultaneously trying to solve it — a race against damage already done, with no guarantee the finish line can be reached.
Bryan Johnson, the 48-year-old tech entrepreneur who has spent millions trying to reverse aging through his Project Blueprint initiative, announced in May that he has autoimmune gastritis—a rare disorder in which the immune system attacks the stomach's lining. The diagnosis arrived as a jolt to someone whose entire public mission centers on defeating death and extending human lifespan through rigorous self-experimentation and data collection.
Johnson revealed the condition in a detailed post on X, describing it with characteristic directness: his stomach is attacking itself. Between two and five percent of the population carries this diagnosis, he noted, though many cases likely go undetected because the disease often produces no symptoms in its early stages. What made his case particularly striking was the timeline—he had been living with autoimmune gastritis for years without knowing it, even as he meticulously tracked hundreds of biomarkers and pursued what he calls "conquering death."
The roots of the condition trace back further than Johnson initially realized. In his childhood, he consumed the typical American diet of sugary cereals, sodas, and fast food. His early twenties brought healthier habits, but then came fatherhood and entrepreneurship. The stress of building a business while raising three children led him to neglect his health. He gained forty pounds and fell into a deep depression. Somewhere in that period, his body began mounting an autoimmune attack—first against his thyroid, which he discovered and managed at age twenty-one with hormone replacement, and later against his stomach lining, which remained hidden for over a decade.
The hidden damage accumulated quietly. For eleven years, Johnson's blood work showed persistently low ferritin levels without accompanying anemia—a pattern his team repeatedly tried to correct through diet and supplements, always without success. Only in May, when he underwent more advanced testing, did the pieces click into place. Autoimmune gastritis causes irreversible damage: it depletes the body of essential nutrients, can trigger anemia, and over time elevates the risk of gastric neuroendocrine tumors. Standard medical practice, Johnson noted with evident frustration, essentially concedes defeat. Doctors manage symptoms but offer no cure.
Yet Johnson's response has been characteristically defiant. Rather than accept the conventional wisdom that nothing can be done, he has assembled a team to pursue experimental approaches. His strategy involves aggressive monitoring—tracking ferritin, iron, B12, pepsinogen ratios, gastrin, and chromogranin A levels. Gastrin is the critical marker; if it rises, the disease is advancing and cancer risk climbs with it. Beyond surveillance, Johnson plans deep characterization of his own immune system: repeat biopsies to examine which immune cells are infiltrating the stomach, cytokine profiling to identify which inflammatory pathways are active, and T-cell subset analysis to pinpoint exactly which immune mechanisms have gone awry.
That data will drive the intervention plan. Johnson intends to develop and test experimental treatments tailored to his specific immune dysfunction. It is, in essence, an extension of the same philosophy that built Project Blueprint—treating the human body as a complex system to be measured, understood, and optimized. The difference is that this time, the stakes are not abstract longevity but concrete survival, and the disease is not aging but an incurable condition that medicine has largely abandoned.
The diagnosis raises uncomfortable questions about the limits of biohacking and self-optimization. Johnson had access to resources, data, and medical expertise that most people will never have. He monitored his body obsessively. And yet autoimmune gastritis still took root and flourished in silence for years. The condition highlights a gap in routine medical screening—most people never get the specific tests that would catch early-stage autoimmune disease. Johnson's wealth and attention to his health gave him an advantage, but not enough of one. Now he faces the prospect of managing an incurable disease while simultaneously trying to solve it, a race against irreversible damage that may or may not be winnable.
Citas Notables
My stomach is eating itself. Standard medical care concedes defeat, stating that nothing can be done except managing the condition.— Bryan Johnson, in his announcement on X
La Conversación del Hearth Otra perspectiva de la historia
So he's spent all this time and money trying to optimize his body, and a disease was growing inside him the whole time without any symptoms. How does that land for someone like him?
It's a particular kind of humbling. Johnson's entire project is built on the idea that if you measure enough, you can control the outcome. But autoimmune gastritis doesn't announce itself. It hides. He had the resources and the obsession with data that most people lack, and it still got past him.
He says standard medicine just gives up—manages the symptoms but doesn't cure it. Is that actually true, or is he being dramatic?
It's true. Autoimmune gastritis is incurable by current medical standards. Once your immune system starts attacking your stomach lining, you can't reverse that damage. You can slow progression, manage deficiencies, reduce cancer risk. But you can't make it go away. That's what makes his response—trying experimental approaches—both understandable and risky.
What's the actual danger here? What happens if he doesn't solve this?
Nutritional deficiency, anemia, and over time, gastric neuroendocrine tumors. The stomach damage is irreversible. So it's a slow accumulation of problems, not a sudden crisis. But the cancer risk is real.
He's been living with this for eleven years without knowing. Does that change how we should think about his whole Project Blueprint thing?
It complicates it. He's been measuring hundreds of biomarkers, optimizing everything, and this was happening underneath it all. It suggests that even extreme self-monitoring has blind spots. The disease doesn't show up in routine tests. Most people never get screened for it at all.
So what's he actually going to do now?
Deep characterization of his own immune system—biopsies, cytokine profiling, T-cell analysis—to understand exactly which immune pathways are firing. Then use that data to design experimental interventions. It's the same approach that built Project Blueprint, but now applied to something that might actually kill him.